These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 28390197

  • 1. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
    Ramos TL, Sánchez-Abarca LI, Redondo A, Hernández-Hernández Á, Almeida AM, Puig N, Rodríguez C, Ortega R, Preciado S, Rico A, Muntión S, Porras JRG, Del Cañizo C, Sánchez-Guijo F.
    Oncotarget; 2017 Apr 25; 8(17):28187-28202. PubMed ID: 28390197
    [Abstract] [Full Text] [Related]

  • 2. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
    Gao SM, Chen CQ, Wang LY, Hong LL, Wu JB, Dong PH, Yu FJ.
    Exp Hematol; 2013 Mar 25; 41(3):261-70.e4. PubMed ID: 23111066
    [Abstract] [Full Text] [Related]

  • 3. Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis.
    Ramos TL, Sánchez-Abarca LI, Rosón-Burgo B, Redondo A, Rico A, Preciado S, Ortega R, Rodríguez C, Muntión S, Hernández-Hernández Á, De Las Rivas J, González M, González Porras JR, Del Cañizo C, Sánchez-Guijo F.
    PLoS One; 2017 Mar 25; 12(8):e0182470. PubMed ID: 28796790
    [Abstract] [Full Text] [Related]

  • 4. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms.
    Hu M, Xu C, Yang C, Zuo H, Chen C, Zhang D, Shi G, Wang W, Shi J, Zhang T.
    J Exp Clin Cancer Res; 2019 Feb 04; 38(1):49. PubMed ID: 30717771
    [Abstract] [Full Text] [Related]

  • 5. Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases.
    Chen CQ, Yu K, Yan QX, Xing CY, Chen Y, Yan Z, Shi YF, Zhao KW, Gao SM.
    Carcinogenesis; 2013 Jul 04; 34(7):1442-9. PubMed ID: 23430957
    [Abstract] [Full Text] [Related]

  • 6. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
    Guru SA, Sumi MP, Mir R, Waza AA, Bhat MA, Zuberi M, Lali P, Saxena A.
    Hum Cell; 2020 Oct 04; 33(4):1099-1111. PubMed ID: 32430672
    [Abstract] [Full Text] [Related]

  • 7. Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms.
    Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, Fernandes JC, Rodrigues Alves APN, Scheucher PS, Simões BP, Alberici LC, de Figueiredo Pontes LL, Tognon CE, Druker BJ, Rego EM, Traina F.
    Cell Death Dis; 2018 Feb 22; 9(3):311. PubMed ID: 29472557
    [Abstract] [Full Text] [Related]

  • 8. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D, Ghazanfari R, Li H, Lim HC, Scheding S.
    Eur J Haematol; 2018 Jul 22; 101(1):57-67. PubMed ID: 29645296
    [Abstract] [Full Text] [Related]

  • 9. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
    Yin LH, Zheng XQ, Li HY, Bi LX, Shi YF, Ye AF, Wu JB, Gao SM.
    Leuk Res; 2015 Apr 22; 39(4):471-8. PubMed ID: 25666256
    [Abstract] [Full Text] [Related]

  • 10. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L, Lambert QT, Pradhan A, Griner LN, Huszar D, Reuther GW.
    Oncotarget; 2015 Nov 24; 6(37):40141-57. PubMed ID: 26472029
    [Abstract] [Full Text] [Related]

  • 11. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
    Amaru Calzada A, Todoerti K, Donadoni L, Pellicioli A, Tuana G, Gatta R, Neri A, Finazzi G, Mantovani R, Rambaldi A, Introna M, Lombardi L, Golay J, AGIMM Investigators.
    Exp Hematol; 2012 Aug 24; 40(8):634-45.e10. PubMed ID: 22579713
    [Abstract] [Full Text] [Related]

  • 12. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells.
    Fenerich BA, Fernandes JC, Rodrigues Alves APN, Coelho-Silva JL, Scopim-Ribeiro R, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado-Neto JA, Traina F.
    Signal Transduct Target Ther; 2020 Jan 24; 5(1):5. PubMed ID: 32296029
    [Abstract] [Full Text] [Related]

  • 13. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.
    Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S.
    Cancer Res; 2011 Jun 01; 71(11):3831-40. PubMed ID: 21512135
    [Abstract] [Full Text] [Related]

  • 14. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
    Hao X, Xing W, Yuan J, Wang Y, Bai J, Bai J, Zhou Y.
    Invest New Drugs; 2020 Jun 01; 38(3):610-620. PubMed ID: 31227936
    [Abstract] [Full Text] [Related]

  • 15. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
    de Melo Campos P, Machado-Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, da Silva Souza Duarte A, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Olalla Saad ST, Traina F.
    Oncotarget; 2016 Feb 09; 7(6):6948-59. PubMed ID: 26755644
    [Abstract] [Full Text] [Related]

  • 16. HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.
    Yue L, Sharma V, Horvat NP, Akuffo AA, Beatty MS, Murdun C, Colin C, Billington JMR, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville LN, Pinilla-Ibarz J, Reuther GW, Wright KL, Conti C, Lee JY, Zheng X, Ng PY, Martin MW, Marshall CG, Koomen JM, Levine RL, Verma A, Grimes HL, Sotomayor EM, Shao Z, Epling-Burnette PK.
    Blood; 2020 Jan 16; 135(3):191-207. PubMed ID: 31750881
    [Abstract] [Full Text] [Related]

  • 17. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.
    FASEB J; 2012 Feb 16; 26(2):894-906. PubMed ID: 22051730
    [Abstract] [Full Text] [Related]

  • 18. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.
    Grimwade LF, Happerfield L, Tristram C, McIntosh G, Rees M, Bench AJ, Boyd EM, Hall M, Quinn A, Piggott N, Scorer P, Scott MA, Erber WN.
    Br J Haematol; 2009 Nov 16; 147(4):495-506. PubMed ID: 19747364
    [Abstract] [Full Text] [Related]

  • 19. Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
    Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH.
    J Cancer Res Clin Oncol; 2017 May 16; 143(5):807-820. PubMed ID: 28233092
    [Abstract] [Full Text] [Related]

  • 20. Regulation of STAT5 phosphorylation and interaction with SHP1 by lnc-AC004893, a long non-coding RNA overexpressed in myeloproliferative neoplasms.
    Yang J, Ruan J, Zhou B, Ye S, Gao S, Zheng X.
    Hematology; 2024 Dec 16; 29(1):2375045. PubMed ID: 39012197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.